CN Patent

CN110944646A — 治疗骨髓增生异常综合征的方法

Assigned to Geron Corp · Expires 2020-03-31 · 6y expired

What this patent protects

本公开提供了在未使用选自低甲基化剂(HMA)和来那度胺或两者的药剂治疗的受试者中治疗骨髓增生异常综合征(MDS)的方法。所述方法包括向所述受试者施用有效量的端粒酶抑制剂，诸如例如伊美司他或伊美司他钠。在一些情况下，所治疗的受试者被分类为低或中度‑1IPSS风险MDS受试者和/或患有红细胞生成刺激剂(ESA)复发性/难治性MDS。

USPTO Abstract

本公开提供了在未使用选自低甲基化剂(HMA)和来那度胺或两者的药剂治疗的受试者中治疗骨髓增生异常综合征(MDS)的方法。所述方法包括向所述受试者施用有效量的端粒酶抑制剂，诸如例如伊美司他或伊美司他钠。在一些情况下，所治疗的受试者被分类为低或中度‑1IPSS风险MDS受试者和/或患有红细胞生成刺激剂(ESA)复发性/难治性MDS。

Drugs covered by this patent

Patent Metadata

Patent number
CN110944646A
Jurisdiction
CN
Classification
—
Expires
2020-03-31
Drug substance claim
No
Drug product claim
No
Assignee
Geron Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.